Several researchers have found a way to check the blood to determine the spread of cancer cells and said they might be able to use these methods to predict cancer, someone who will relapse after treatment.
The team from Harvard Medical School and Massachusetts General Hospital using the assistance of a non-profit groups to conduct these tests, which they did in the example of the 20 men who suffer from prostate cancer.
They found that circulating tumor cells in all patients with tumors that did not did not spread, low-level cancer and prostate gland in patients, they were appointed three months earlier.
“These are all groups of patients who are normally in the body they found no tumor cells in circulation, so it gave us so much information about the risks they face,” said Sunithat Nagrath of Harvard, who led the study, as cited by the British news agency, Reuters.
“Are all of these patients more susceptible to recurrence of their disease?” he questioned in a briefing during the meeting of the American Association for Cancer Research.
He said his team will follow the development of these patients to see if the tumor recurrence in patients who have cancer cells in circulation.
Such experiments may also one day serve as a blood test for prostate cancer than PSA or prostate specific antigen examination, looking for proteins that are made only by prostate cells and which can indicate cancer.
Nagrath said the inspection team were able to detect circulating tumor cells 200 of a teaspoon of blood drawn from a patient with cancer.
Prostate cancer is the leading killer cancer for men after lung cancer. But it is a disease that often develops slowly and the doctors do not believe any man who has the most deadly types of cancer and which men are most likely to spread or recurrence of cancer.
The researchers find tumor cells circulating in the blood one day and nine days after all he was undergoing prostate removal, and then do it again more than three months later.
They found the cells in 42 percent of patients, and in 64 percent of patients with advanced prostate cancer.
These cells could not be found immediately after the operation but it emerged again in some patients.
Nagrath said would be important to follow the development of these men to see how well their condition and whether patients with more circulating cells facing worse conditions.
He also said that trials may be useful for monitoring patients who are referred to therapeutic target, which affects the cancer cells with a particular genetic mutation.
“With blood tests you can take a sample of patients each day to see if the genotype changed,” said Nagrath. The charity “Stand Up To Cancer” fund the experiment.
0 comments:
Post a Comment